

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>  
24th April 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Manager Ami Kira
MAIL :	info@chorditherapeutics.com

## **Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2026**

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) held a “Briefing on interim financial results for the fiscal year ending August 31, 2026” on Tuesday, April 14, 2026, and the transcript of the event (including the Q&A session) has been published on Logmi Finance. During the briefing, the progress of the clinical development of our lead pipeline, rogocekib (CTX-712), in the United States and our interim financial results were presented.

We believe that this publication will help bridge the information gap between investors and the company and lead to a deeper understanding of our business, and we will continue to strive for fair information disclosure.

### **1. Overview**

Date	:	Tuesday, April 14, 2026, 16:00 - 16:30 (JST)
Presenter	:	Hiroshi Miyake, Chief Executive Officer
Method of holding	:	Web-based

### **2. Transcript article URL**

<https://finance.logmi.jp/en/articles/383894>

### **About Chordia Therapeutics**

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177), CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.